-
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
NCT07317505 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT06270706 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Wilson
-
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)
NCT07058012 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Pinehurst
-
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
NCT07217171 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
NCT07488676 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
NCT06662786 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
NCT06778863 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of DM002 in Patients With Advanced Solid Tumors
NCT06751329 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
NCT07213791 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
NCT05877599 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Winston-Salem
-
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A Study of PHN-012 in Patients With Advanced Solid Tumors
NCT07127874 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
NCT03093116 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· North Carolina: Goldsboro
-
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Pinehurst
-
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors
NCT07749586 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
NCT06820463 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
NCT07221357 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte
-
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
NCT07235293 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
NCT07094113 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
NCT03175224 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069 ·
Phase: Not specified ·
Ages: 40 Years to 75 Years ·
Sex: All (male and female)
· North Carolina: Asheville, Cary, Clinton, Clyde
-
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Cary, Chapel Hill, Charlotte, Clinton
-
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
NCT05612347 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 65 Years to 82 Years ·
Sex: All (male and female)
· North Carolina: Charlotte
-
DESTINY-PANTUMOUR04
NCT07124000 ·
Phase: Not specified ·
Ages: 18 Years to 130 Years ·
Sex: All (male and female)
· North Carolina: Durham, Wilson
-
Distance-Based Exercise to Preserve Function and Prevent Disability
NCT07059884 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Kernersville, Mount Airy, Winston-Salem
-
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
NCT06848348 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Winston-Salem
-
Engage Psychosocial Intervention for Cancer Symptoms
NCT06555588 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors
NCT07018869 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Asheboro, Burlington, Greensboro, Hendersonville
-
Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas
NCT00843375 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
FOG-001 in Locally Advanced or Metastatic Solid Tumors
NCT05919264 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Family Communications After Genetic Testing
NCT07143487 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Clinton, Gastonia, Goldsboro, Jacksonville
-
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
NCT05080673 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 45 Years to 70 Years ·
Sex: All (male and female)
· North Carolina: Clinton, Goldsboro, Jacksonville
-
Increasing Germline Genetic Testing for Patients With Cancer
NCT07307664 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Durham, Salisbury
-
Integrated Cancer Repository for Cancer Research
NCT02012699 ·
Phase: Not specified ·
Ages: 19 Years to 110 Years ·
Sex: All (male and female)
· North Carolina: Fayetteville
-
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06586515 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer
NCT03998202 ·
Phase: Not specified ·
Ages: 60 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Clemmons, Concord, Gastonia
-
Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer
NCT06205485 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Greenville
-
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT06896162 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Chapel Hill
-
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Pilot Study for Colorectal Cancer and Advanced Adenoma Detection With the Mainz Biomed Colorectal Cancer Test
NCT06864338 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Morrisville
-
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
NCT07351071 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT03452774 ·
Phase: Not specified ·
Ages: No age limits stated ·
Sex: All (male and female)
· North Carolina: Chapel Hill, Winston-Salem
-
Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy
NCT06937177 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Shield Post-Approval Study Protocol
NCT06880055 ·
Phase: Not specified ·
Ages: 45 Years to 81 Years ·
Sex: All (male and female)
· North Carolina: Cary, Chapel Hill, Hillsborough, Mocksville
-
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
NCT07030257 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Huntersville
-
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
NCT03947385 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Raleigh
-
Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
NCT05855200 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT06445062 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Huntersville
-
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
NCT04429542 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte
-
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
NCT06252649 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Pinehurst
-
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
NCT05433142 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Durham
-
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
NCT05176483 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham
-
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
NCT05005403 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Huntersville
-
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NCT07283939 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Pinehurst
-
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
NCT07222800 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Cary, Durham, Raleigh
-
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
NCT06371768 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 39 Years ·
Sex: All (male and female)
· North Carolina: Durham
-
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Goldsboro
-
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT05863195 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Durham, Raleigh, Winston-Salem
-
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
NCT05673148 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· North Carolina: Charlotte, Concord, Greenville, Winston-Salem
-
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT04585750 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female)
· North Carolina: Durham